CiVi Biopharma

Executive Summary

CiVi Biopharma is a private biotech company focused on developing novel oral antisense oligonucleotide therapies for vascular and fibrotic conditions. Its lead candidate, CiVi 030, is an intravenous formulation of iloprost currently in Phase 3 clinical trials for the treatment of severe frostbite, leveraging its potent vasodilatory, anti-inflammatory, and anti-fibrotic properties. The company also has a preclinical pipeline, including CiVi 008, a third-generation antisense program aimed at additional indications. With a limited public track record and a single late-stage asset, CiVi Biopharma represents a speculative opportunity in the RNA therapeutics space, with near-term value dependent on successful Phase 3 readouts and pipeline advancement.

Upcoming Catalysts (preview)

• Q1 2027Phase 3 Top-line Data for CiVi 030 in Severe Frostbite50% success
• H2 2027IND Filing or Phase 1 Initiation for Oral Antisense Candidate30% success
• 2026Strategic Partnership or Licensing Deal for Antisense Platform40% success